Filing identity and reporting period
Important identity discrepancy: The provided filing is for Nuvilex, Inc., not Pharmacyte Biotech, Inc. It is a Form 10-Q for the quarter ended January 31, 2013, covering the three- and nine-month periods ended on that date. The filing identifies Nuvilex as a smaller reporting company; its interim financial statements are unaudited.
Business context
Nuvilex described a shift toward biotechnology and pharmaceutical activities, including work with Austrianova Singapore Private Limited (ASPL) and development of a pancreatic-cancer treatment. Management said legacy products were not being offered for sale while limited funds were directed to the parent company and the ASPL relationship. The ASPL transaction remained subject to financing and escrow conditions.
Financial performance and position
| Metric | Three months ended Jan. 31 | Nine months ended Jan. 31 |
|---|---|---|
| Revenue | 2013: $0; 2012: $20,271 | 2013: $12,160; 2012: $59,877 |
| Gross profit | 2013: $0; 2012: $18,060 | 2013: $2,540; 2012: $35,955 |
| Operating expenses | 2013: $340,840; 2012: $428,043 | 2013: $1,231,715; 2012: $1,502,267 |
| Net loss | 2013: $376,843; 2012: $271,779 | 2013: $1,270,929; 2012: $1,394,949 |
| Operating cash flow | Nine months: cash used of $247,475 in 2013 versus $207,334 in 2012 |
For the nine-month period, gross margin was approximately 21% ($2,540 gross profit on $12,160 revenue). The filing reports basic loss per share rounded to $(0.00).
At January 31, 2013, cash was $33,334; total current assets were $1,422,168 and current liabilities were $3,608,275, producing negative working capital of $2,186,107. Total liabilities were $3,900,275, compared with total assets of $2,450,946; stockholders’ deficit was $2,029,329. Current loans payable were $420,000 and related-party long-term debt was $292,000. Settlement-obligation liabilities were $2,302,508. Cash declined by $18,124 in operating activities and $481,750 of investing outflows for acquisition payments were partly offset by $746,836 in financing inflows; ending cash increased $17,611 from the beginning of the period.
Common shares outstanding increased from 416,293,195 at April 30, 2012 to 457,942,825 at January 31, 2013; 459,782,825 were outstanding as of March 25, 2013. The 100 million shares associated with the ASPL transaction were held in escrow and excluded from reported shares outstanding.
Changes, outlook, and risks
- Nine-month net loss improved by $124,020 year over year, mainly as compensation and sales-and-marketing expenses declined; operating expenses fell $270,552. Quarterly net loss worsened by $105,064, reflecting lower gains from debt forgiveness and settlement.
- Management said the ASPL agreement required $2.5 million in future funding and monthly operating support of $60,000; the parties extended the arrangement through the first quarter of 2013, then subsequently through the second quarter. The filing does not establish that the financing condition was completed.
- The company reported a $400,000 obligation for terminated licensing fees under negotiation for settlement. It also described a Cornerstone Bank settlement involving a judgment of $1,975,889 as of May 16, 2012, accruing interest at 7.75%, supported by property and pledged shares; the property and collateral had not yet been sold.
- Management and the filing identify substantial going-concern uncertainty: minimal revenue, accumulated deficit of $41,118,934, negative working capital, and reliance on management, shareholders, and outside investors for funding. The company warned that failure to obtain capital could materially harm its business and liquidity.
- The private-placement memorandum sought to raise $3.5 million to $5.0 million. The filing reports $742,458 in placement proceeds during the period and a further $62,500 received afterward. No revenue or earnings guidance was provided.
- Management concluded internal controls over financial reporting were ineffective at January 31, 2013, citing material weaknesses, including incomplete accounting procedures and the absence of a board audit-committee financial expert. Remediation was ongoing.
- Subsequent events included formation of a wholly owned subsidiary for cannabis-derived research and development and issuance of 1,840,000 shares for services.
Most important facts for investors to verify
- Confirm the filing belongs to the intended issuer: this document names Nuvilex, not Pharmacyte Biotech.
- Check the status and funding requirements of the ASPL transaction, including escrowed shares, monthly support, and the $2.5 million funding condition.
- Verify available liquidity, financing raised after the reporting date, and the company’s ability to meet obligations given negative working capital and the going-concern warning.
- Review the Cornerstone settlement, property sale and collateral status, and resolution of the $400,000 licensing-fee obligation.
- Assess share dilution, including placement shares, shares issued for compensation and services, warrants, and the escrowed ASPL shares.
- Track remediation of the disclosed material weaknesses and any subsequent changes in reporting controls.